BIOMAT Database Logo BIOMAT Database Logo

Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol. 1995

R Schall, and F O Müller, and L Duursema, and G Groenewoud, and H K Hundt, and M V Middle, and E M Mogilnicka, and K J Swart
Farmovs Institute for Clinical Pharmacology and Drug Development, Department of Pharmacology, University of the Orange Free State, Bloemfontein, Republic of South Africa.

Twenty male volunteers who were slow metabolisers of isoniazid, completed this single-blind, single-dose, randomised, cross-over study to compare the bioavailability of rifampicin (CAS 13292-46-1), isoniazid (CAS 54-85-3) and ethambutol (CAS 1070-11-7) from Myrin tablets (test preparation) with the bioavailability of these drugs from a combination of capsules containing rifampicin and tablets containing isoniazid and ethambutol (reference). There were 2 treatment periods and on clinic days volunteers were given either the reference (300 mig rifampicin plus 200 mg isoniazid and 600 mg ethambutol HCl), or the test preparation (300 mg rifampicin, 150 mg isoniazid and 600 mg ethambutol HCl). Serial blood samples were drawn from the volunteers and rifampicin, isoniazid and ethambutol assays were performed. The results of this study indicate that the test preparation is equivalent to the reference with respect to both the rate and the extent of absorption of rifampicin, isoniazid (after adjustment for the different doses of isoniazid and ethambutol).

UI MeSH Term Description Entries
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D008297 Male Males
D002214 Capsules Hard or soft soluble containers used for the oral administration of medicine. Capsule,Microcapsule,Microcapsules
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004977 Ethambutol An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863) Dexambutol,EMB-Fatol,EMB-Hefa,Etambutol Llorente,Ethambutol Hydrochloride,Etibi,Miambutol,Myambutol,EMB Fatol,EMB Hefa,Hydrochloride, Ethambutol,Llorente, Etambutol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000904 Antibiotics, Antitubercular Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and may be toxic. Antitubercular Antibiotics
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular

Related Publications

R Schall, and F O Müller, and L Duursema, and G Groenewoud, and H K Hundt, and M V Middle, and E M Mogilnicka, and K J Swart
Bioavailability of rifampicin following concomitant administration of ethambutol or isoniazid or pyrazinamide or a combination of the three drugs.
September 2003, The Indian journal of medical research,
R Schall, and F O Müller, and L Duursema, and G Groenewoud, and H K Hundt, and M V Middle, and E M Mogilnicka, and K J Swart
[Comparative study: Streptomycin, Isoniazid (Ethambutol) vs. Rifampicin, Isoniazid (Ethambutol)].
January 1971, Pneumonologie. Pneumonology,
R Schall, and F O Müller, and L Duursema, and G Groenewoud, and H K Hundt, and M V Middle, and E M Mogilnicka, and K J Swart
Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
October 2002, International journal of clinical pharmacology and therapeutics,
R Schall, and F O Müller, and L Duursema, and G Groenewoud, and H K Hundt, and M V Middle, and E M Mogilnicka, and K J Swart
Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
October 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
R Schall, and F O Müller, and L Duursema, and G Groenewoud, and H K Hundt, and M V Middle, and E M Mogilnicka, and K J Swart
Serum concentrations and bioavailability of rifampicin and isoniazid in combination.
October 1976, British journal of clinical pharmacology,
R Schall, and F O Müller, and L Duursema, and G Groenewoud, and H K Hundt, and M V Middle, and E M Mogilnicka, and K J Swart
Toxic overdose of isoniazid, rifampicin and ethambutol.
January 1986, European journal of clinical pharmacology,
R Schall, and F O Müller, and L Duursema, and G Groenewoud, and H K Hundt, and M V Middle, and E M Mogilnicka, and K J Swart
Toxicity form rifampicin plus isoniazid and rifampicin plus ethambutol therapy.
September 1971, Tubercle,
R Schall, and F O Müller, and L Duursema, and G Groenewoud, and H K Hundt, and M V Middle, and E M Mogilnicka, and K J Swart
[Comparative hepatic toxicity of isoniazid, rifampicin and ethambutol].
January 1991, Problemy tuberkuleza,
R Schall, and F O Müller, and L Duursema, and G Groenewoud, and H K Hundt, and M V Middle, and E M Mogilnicka, and K J Swart
The treatment of tuberculosis of the skin with a combination of rifampicin, ethambutol and isoniazid.
January 1972, Dermatologica,
R Schall, and F O Müller, and L Duursema, and G Groenewoud, and H K Hundt, and M V Middle, and E M Mogilnicka, and K J Swart
Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation.
October 2001, International journal of pharmaceutics,
Copied contents to your clipboard!